PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer

Huijie Duan1,2, Zhong Lei3, Fei Xu4, Tao Pan5, Demin Lu1,2, Peili Ding2, Chunpeng Zhu6, Chi Pan* and Suzhan Zhang2,*

1 Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 2 Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, The Second Affiliated Hospital, School of Medicine, Cancer Institute, Zhejiang University, Hangzhou, China, 3 Department of Orthopedics Research Institute, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 4 Department of Oncology, Municipal Hospital of Qingdao, Qingdao, China, 5 Department of Breast Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 6 Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 7 Research Center for Air Pollution and Health, School of Medicine, Zhejiang University, Hangzhou, China

Aims: PARK2 mutation is originally associated with the progression of Parkinson’s disease. In recent years, PARK2 has been reported as a tumor suppressor gene in various cancers, including lung cancer. However, the biological functions and potential molecular mechanisms of PARK2 in non-small cell lung cancer (NSCLC) are still unclear.

Methods: The level of PARK2 expression in 32 tissue samples of NSCLC and matched non-tumor lung tissues was detected by Western blot, and 64 specimens of NSCLC tissues were detected by immunohistochemistry. H1299 and H460 cell lines were used to PARK2 overexpression models, and H460 cell line was also used to PARK2 knockdown model. Using cell viability, colony formation, cell cycle, apoptosis, migration, and invasion assay, the biological functions of PARK2 were evaluated and the potential molecular mechanism of PARK2 was investigated in vitro. Meanwhile, 22 nude mice were employed for in vivo studies.

Results: Western blot analysis revealed a decrease of PARK2 protein expression in human NSCLC samples. Immunohistochemistry also identified a vastly reduced expression of PARK2 in NSCLC (72%) and low PARK2 expression was significantly associated with tumor histological grade, lymph node metastasis and advanced TNM stage. Overexpression of PARK2 suppressed cell proliferation, colony formation, migration, and invasion, arrested cell cycle progression in the G1 phase, and induced apoptosis in human non-small cell lines H1299 and H460 in vitro. Meanwhile, knockdown of PARK2 had the opposite biological functions. In addition, PARK2 significantly decreased the tumor volumes in subcutaneous xenograft model and reduced the incidence of metastatic tumors in the transfer model. Exploration of the molecular mechanism of PARK2 in NSCLC showed that PARK2 negatively regulated the EGFR/AKT/mTOR signaling pathway.
**INTRODUCTION**

Lung cancer is the leading cause of cancer death globally. Approximately 1.8 million new lung cancer cases are recorded annually, and the number increases every year (1, 2). In China, lung cancer is the most commonly diagnosed type of cancer, attributable in large part to smoking and severe air pollution (3). Approximately 57% of lung cancers are diagnosed at the advanced stage because it is typically asymptomatic early. Consequently, the 5-year survival rate is only 27% for regional cases and 4% for advanced cases (4, 5). Non-small cell lung cancer (NSCLC) accounts for the largest proportion (~85%) of lung cancer (6). Fully understanding the pathogenesis and characters of lung cancer would be helpful to clinical treatment. In past decades, numerous studies have shown that lung cancer genesis and progression are associated with the mutation, deletion, inactivation, and abnormal expression of oncogenes and anti-oncogenes. Several genes related to lung cancer were identified, such as epidermal growth factor receptor (EGFR) and ALK (7, 8). Understanding the functions and underlying mechanisms of these genes is essential to the diagnosis, treatment, and prognosis of lung cancer. However, plenty of genes and their functions and mechanisms remain largely unknown in lung cancer. Thus, it is necessary to investigate the genes related to the occurrence and development of lung cancer on metabolism function and molecular level.

**PARK2** is located on the long arm of chromosome 6q25.2–q27 and was first reported for its role in the pathogenesis of autosomal recessive juvenile parkinsonism (9). **PARK2** encodes a RING-between-RING E3 ubiquitin ligase, which mediates protein degradation through the ubiquitin–proteasome system (10–14). The chromosome 6q25.2–q27 is a fragile region and prone to breakage and rearrangement, with ~500 breakpoint junctions involving **PARK2** (11). Studies have illuminated that **PARK2** associated with protein turnover, stress response, mitochondria, homeostasis, autophagy, metabolism, and many other cellular processes regulating cell growth and survival (15). Cesari et al. revealed that the loss of heterozygosity observed at chromosome 6q25–q26 leads to a hypernormal gene expression product by excessive transcription and translation. **PARK2** shRNA (sequence: 5′-GCACCTGATCGCAACAAATAG-3′) was constructed using the

**Conclusions:** **PARK2** was an important tumor suppressor in NSCLC, which might inhibit cancer growth and metastases through the down regulation of the EGFR/AKT/mTOR signaling pathway.

**Keywords:** **PARK2**, non-small cell lung cancer, proliferation, metastasis, EGFR/AKT/mTOR

**MATERIALS AND METHODS**

**Tissue Samples**

Human NSCLC tissue samples and its adjacent non-tumor lung tissues were obtained by surgical resection from the Biobank at the Second Affiliated Hospital of Zhejiang University School of Medicine. Thirty-two pairs of specimens were stored at −80°C after surgery and another 64 pairs of specimens were paraffin-embedded tissues. The frozen and paraffin-embedded samples were not from the same donor. All tumor samples were confirmed by two different pathologists and classified according to the 7th AJCC-TNM classification of tumors. Patients were pre-operatively examined by CT and MRI scans and/or biopsy before the surgical resection. This project was approved by the Institutional Medical Ethics Committee of the Second Affiliated Hospital of Zhejiang University, and obtaining informed consent before the patients undergo surgery.

**Cell Lines and Cultivation**

Human NSCLC cell lines, H1299 and H460, were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Both cell lines were maintained in Roswell Park Memorial Institute (RPMI 1640; Gibco, USA) medium supplemented with 10% heat-inactivated fetal bovine serum (Yeasen, Shanghai, China) and 1% penicillin/streptomycin. All cells were incubated at 37°C in 5% CO₂ incubator with a humidified atmosphere.

**Lentivirus Transfection**

The overexpressed **PARK2** lentivirus vector, **PARK2** small hairpin RNA (shRNA) and negative control were obtained from GenePharma Corporation (Shanghai, China). The cDNA sequence of **PARK2** was obtained from GenBank (NM_004562.2). The full length of **PARK2** was synthesized and overexpressed using the LV5/EF-1aF/GFP/Puro vector. This artificially makes **PARK2** gene overexpression and ultimately leads to a hypernormal gene expression product by excessive transcription and translation. **PARK2** shRNA (sequence: 5′-GCACCTGATCGCAACAAATAG-3′) was constructed using the
LV3/pGLVH1/GFP/Puro vector and was utilized to knock down the expression of PARK2. By specifically degrading mRNA with homologous sequence of PARK2 gene, it can prevent PARK2 gene expression in the cell. Cells were transfected according to the manufacturer's instructions. After co-culture of the viral particles for 48 h, the medium containing 3 µg/mL puromycin was used to screen stable cell lines for a total of 10 to 14 days. Stable PARK2 overexpressing cell lines or knockdown cell lines were confirmed by qRT-PCR, Western blot and immunofluorescence assay.

Cell Proliferation Assay
Cells were plated at a density of 3,000 cells/well into 96-well-plates. The cell proliferation assay was assessed using the cell counting kit-8 (Yeasen, Shanghai, China) and was measured at an absorbance of 450 nm according to the manufacturer's instructions.

Colony Formation Assay
A total of 200 cells/well were seeded into 6-well-plates, and the medium was refreshed every 2 to 3 days to observe anchorage-independent growth. After 2 weeks, colonies, which were defined as co-localized cell groups of more than 50 cells, were counted using the ImageJ analysis software.

Wound Healing Assay
Cells were seeded into 6-well plates and grown to ~90% confluence. An artificial straight wound was scratched with a 10 µL tip through the cell monolayer. Afterward, the culture medium was replaced with serum-free culture medium. Images were obtained at 0 and 24 h (H1299) or 36 h (H460). The wound healing areas were counted using the ImageJ analysis software.

Transwell Migration and Invasion Assays
Cell migration and invasion assays were performed using 24-well transwell plates (8 µm pore size; Costar, USA). Then, 5 x 10^4 cells were loaded onto the upper chambers with the serum-free medium, whereas the RPMI 1640 medium plus 10% fetal bovine serum was loaded onto the lower chamber. After 16 h incubation at 37°C in 5% CO₂ incubator, the cells migrated to the underside of the filters. Then, the cells on the upper side of the polycarbonate membrane were wiped off and stained with crystal violet. Data on the number of migrated cells are measured at an absorbance of 450 nm according to the manufacturer's instructions. After co-culture of the viral particles for 48 h, the medium containing 3 µg/mL puromycin was used to screen stable cell lines for a total of 10 to 14 days. Stable PARK2 overexpressing cell lines or knockdown cell lines were confirmed by qRT-PCR, Western blot and immunofluorescence assay.

Cell Apoptosis Assay
The cells were seeded into 6-well-plates overnight. After serum-free starvation treatment for 48 h, the cells were collected, stained with Annexin V–APC/7-aminoactinomycin D (7-AAD) (MultiSciences, Hangzhou, China) following the manufacturer's instructions and detected with a BD FACSCalibur flow cytometer (Becton Dickinson, USA).

Protein Extraction and Western Blot Assay
Proteins were extracted in RIPA buffer (Beyotime, China) containing a protease inhibitor cocktail and a phosphatase inhibitor (Bimake, USA) and determined by the BCA assay kit (Thermo, USA). After polyacrylamide gel electrophoresis, proteins were transferred to a PVDF membrane and incubated overnight at 4°C with specific primary antibodies. Antibodies against PARK2 (ab15954), CDK2 (ab32147), mTOR (ab2732), p-mTOR (ab109268), EGFR (ab52894), p-EGFR (ab40815), and AKT (ab8805) were purchased from Abcam (Cambridge, MA, USA). E-cadherin (3195), N-cadherin (13116), vimentin (5741), slug (9585) claudin-1 (13255), cyclin D1 (2978), CDK4 (12790), cyclin D3 (2936), P21 (2947), P18 (2896), cleaved caspase-3 (9664), cleaved caspase-8 (8592), cleaved caspase-9 (20750), cleaved PARP (5625), Cytochrome c (11940), p-AKT (4060), and GAPDH (2118) were obtained from Cell Signaling Technology (Boston, USA). The goat anti-rabbit IgG–HRP (HA1001-100) and goat anti-mouse IgG–HRP (HA1006) were obtained from HuaAn Biotechnology (Huabio, China). Then the PVDF membrane was incubated with secondary antibody at room temperature for 1 h. The membranes were observed with the SuperSignal West Pico Chemiluminescent Substrate (Thermo, USA). Band intensity was analyzed with Quantity One.

Quantitative Real-Time-Polymerase Chain Reaction
Total RNA was extracted from cell lines and tissues using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) per the manufacturer's instruction. cDNA was synthesized with the PrimeScript™ RT Master Mix (TaKaRa, Japan). qRT-PCR was performed using the SYBR Premix Ex Taq™ II (TaKaRa, Japan) on a StepOnePlus Real-Time PCR system (Life Technologies, Foster, CA, USA). The relative level of gene expression was described as 2^-DeltaCt (ΔCt = CtPARK2 - CtGAPDH). PARK2 primers were synthesized by Sangon Biotech (Shanghai, China) and GAPDH was used as a loading control. The sequences of the primer sets were forward 5'-ATCGCAACAAATAGTCGG-3' and reverse 5'-GGAGCGAGATCCCTCCAAAAT-3 for PARK2; forward 5'-GGAGGGAGATCCCTCAAAAAT-3' and reverse 5'-GGCTGGTGTCACTTTCTCATGG-3' for GAPDH.

Immunohistochemistry (IHC)
Tumor tissue specimens were fixed with 4% paraformaldehyde and embedded in paraffin. Then, all sliced sections (5 µm) were de-paraffinized with xylene and ethanol. The subsequent steps were performed according to the manufacturer's instructions. Sections were incubated with primary PARK2 antibody (ab15954; Abcam), Ki-67 (ab15580; Abcam, USA) and visualized with secondary antibody (Beiyotime Institute of Biotechnology,
China). The percentage of positive immunostaining was scored from 0 to 4 (0, <5; 1, 5 to 25%; 2, 26 to 50%; 3, 51 to 75%; and 4, above 75%). The staining intensity was scored as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. When the staining was heterogeneous, each component was scored independently (multiplying the intensity score and the area score) and received an overall assessment that translated into the indexes (−, score 0), (+, score 1∼4), (++, score 5∼8), and (+++, score 9∼12). Each tissue section was assessed by three independent pathologists. The immunohistochemical results were categorized into negative (−) and positive expression (+∼ + ++).

**Immunofluorescence**

For immunofluorescence assay, the cells were fixed in 4% paraformaldehyde, incubated in 0.1% Triton-X100 and washed with PBS. The cells were stained with primary PARK2 antibody (ab15954; Abcam, USA). Afterward, the cells were counterstained with DAPI (Sigma, USA). Images were acquired by confocal laser scanning microscopy (Zeiss LSM710, Germany). Cell nuclei were stained with Hoechst 33342 (Beyotime Institute of Biotechnology, China) to observe apoptosis. Cells were processed following the manufacturer's instructions and observed at 461 nm by ultraviolet light. Images were acquired by fluorescent microscopy (Zeiss Axio Vert.A1, Germany).

**Tumor Xenograft Assay**

Five-week-old female athymic mice (BALB/cnu/nu) were ordered from the Experimental Animal Center of Zhejiang Chinese Medical University. H1299-PARK2 and H1299-NC cell lines were harvested and injected subcutaneously into the right flank (5 × 10⁶ cells in 200 µL PBS for the subcutaneous xenograft model, six mice per group) and intravenously into the tail vein (1 × 10⁶ cells in 100 µL PBS for the metastatic model, five mice per group) of each mouse. Mice were euthanized at weeks 4 or 6. All animal procedures complied with the Zhejiang University Laws for Animal Experiments Administration and Implementation and were approved by the Zhejiang Medical University Animal Protection Committee.

**Statistics**

Each experiment was performed in triplicate and independently repeated at least three times. All data were presented as the mean ± standard error of the mean. GraphPad Prism 5.0 was used to generate graphs. Statistical analyses were conducted using the SPSS 21.0 statistical software. Student's t-test was performed with paired comparisons. Pearson chi-square test was used for analysis between the results of IHC staining and clinical parameters. P < 0.05 was considered statistically significant.

**RESULTS**

**PARK2 Is Underexpressed in Human NSCLC Tissues and Cell Lines**

Initially, we evaluated PARK2 expression in human NSCLC tissues and adjacent non-tumor lung tissues (n = 32) by Western blot assay. PARK2 was significantly decreased in NSCLC tissues vs. its adjacent non-tumor lung tissues (P < 0.05; Figure 1A), and the clinical characters were detailed in Table 1. Using IHC assay, we detected PARK2 in 64 paraffin-embedded NSCLC tissues with the purpose to further explore the correlations between PARK2 expression and the clinicopathologic features of NSCLC (Figure 1B). The positive rate of IHC among NSCLC tissue samples was 28% (18/64), whereas, 72% (46/64) stained negative for PARK2. Low expression of PARK2 was closely correlated to advanced TNM stage, lymph node metastasis and histological grade in NSCLC (Table 2).

Next, we consulted the Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle) database to show the level of PARK2 mRNA expression in H1299, HCC827, H1975, and H460 cell lines. The results showed that the lowest expression of PARK2 mRNA was observed in H1299 cells, and the highest expression was observed in H460 cells. Additionally, the H460 cell line (human large cell lung cancer cell line) and the H1299 cell line are human NSCLC cell lines, which are representative and suitable cell lines for this study.

**Overexpression and Knockdown of PARK2 Are Observed in NSCLC Cells**

A PARK2 overexpression lentivirus vector and a negative control lentivirus vector were stably transfected into H1299 cells (H1299-PARK2 vs. H1299-NC) and H460 cells (H460-PARK2 vs. H460-NC), respectively. A small hairpin RNA-PARK2 (sh-PARK2) lentivirus vector and a sh-negative control lentivirus vector were stably transfected into the H460 cells (H460-shPARK2 vs. H460-shNC). The transfection results showed that the level of PARK2 mRNA and protein in H1299-PARK2 and H460-PARK2 cells were significantly increased after overexpression. The level of PARK2 mRNA and protein in H460-shPARK2 cells were obviously decreased after knockdown compared with their control group (P < 0.05), as detected by quantitative real-time-polymerase chain reaction (qRT-PCR) and Western blot (Figures 1C,D). The immunofluorescence assay further confirmed that PARK2 was located in the nucleus and cytoplasm, and the level of expression significantly increased or decreased after PARK2 overexpression or knockdown (Figure 1E). Then, the stable transfection cells were used to investigate the potential role of PARK2 in NSCLC.

**Overexpression of PARK2 Suppresses NSCLC Cell Proliferation and Colony Formation**

Compared with control cells, overexpression of PARK2 in H1299 and H460 cells significantly suppressed cell growth (P < 0.05; Figure 2A) and the potential of colony formation (P < 0.05; Figure 2B). Consistently, Ki-67 staining showed that the overexpression of PARK2 led to fewer proliferating cells compared with control cells in H1299 and H460 cell lines (H1299: 28.99 ± 5.29 vs. 50.74 ± 3.26%; H460: 34.17 ± 6.48 vs. 60.8 ± 4.89%; P < 0.05; Figure 2C).
Overexpression of PARK2 Inhibits the NSCLC Cell Cycle

Exploration of the suppressive effects of PARK2 on cell growth by flow cytometry assay showed that the overexpression of PARK2 significantly arrested cell cycle distribution. H1299-PARK2 increased the percentage of G1 phase cells and decreased the percentage of S phase cells compared with H1299-NC (G1 phase: 49.14 ± 1.05 vs. 43.37 ± 1.41%; S phase: 41.51 ± 1.28 vs. 45.73 ± 0.51%; P < 0.05; Figure 2D). H460-PARK2 increased the percentage of G1 phase cells and decreased the percentage of G2 phase cells compared with H460-NC (G1 phase: 60.82 ± 1.64 vs. 54.77 ± 0.66%; G2 phase: 4.41 ± 0.56 vs. 7.24 ± 0.82%; P < 0.05; Figure 2D). Consistently, PARK2 regulated the expression of several key proteins in the cell cycle, which was verified by Western blot. G1, S, and G2 phase cell cycle arrest was confirmed by the reduced expression of cell cycle progression regulators, such as cyclin D1, CDK4, cyclin D3, and CDK2, and the elevated expression of cell cycle inhibitors, such as P18 and P21 (Figure 2E).

Overexpression of PARK2 Induces NSCLC Cell Apoptosis

Flow cytometry verified that the overexpression of PARK2 induced a significant increase in total apoptotic cells compared to negative control (H1299: 24.05 ± 0.89 vs. 20.72 ± 0.74%; H460: 16.86 ± 1.07 vs. 11.45 ± 0.23%; P < 0.05; Figure 3A). Compared
TABLE 2 | Clinicopathologic features and the expression status of PARK2 in 64 NSCLC patients.

| Parameter                | Case   | PARK2 expression | P-value |
|--------------------------|--------|------------------|---------|
|                          |        | Negative         | Positive|         |
| Sex                      |        |                  |         |
| Male                     | 39     | 18               | 11      | 1.000   |
| Female                   | 25     | 18               | 7       |         |
| Age (years)              |        |                  |         |
| ≤60                      | 31     | 21               | 10      | 0.581   |
| >60                      | 33     | 25               | 8       |         |
| Histological grade       |        |                  |         |
| Well                     | 19     | 8                | 11      | 0.002   |
| Moderate or poor         | 45     | 38               | 7       |         |
| Tumor invasion           |        |                  |         |
| T1–T2                    | 50     | 35               | 15      | 0.739   |
| T3–T4                    | 14     | 11               | 3       |         |
| Lymph node               |        |                  |         |
| N0                       | 40     | 25               | 15      | 0.044   |
| N1-2                     | 24     | 21               | 3       |         |
| TNM stage (AJCC)         |        |                  |         |
| I                        | 35     | 21               | 14      | 0.026   |
| II-III                   | 29     | 25               | 4       |         |

Duan et al. PARK2 Suppresses Tumorigenicity in NSCLC

expression of E-cadherin and decreased that of N-cadherin, vimentin, slug, and claudin-1 in the H1299-PARK2 and H460-PARK2 cell lines vs. control groups.

Knockdown of PARK2 Enhances Cell Viability, Increases Cell Cycle Progression, Promotes Cell Migration and Invasion, and Reduces Cell Apoptosis in vitro

Knockdown of PARK2 significantly increased cell growth and colony formation compared with negative control groups (Figures 4A,B). In the transwell migration and wound healing assays, knockdown of PARK2 promoted cell migration (Figures 4C,E). Invasion of the H460 cell line was enhanced by knockdown of PARK2 in the transwell invasion assay (Figure 4D). Knockdown of PARK2 reduced cells in the G1 phase and increased cells in the G2 phase (Figure 4F), further decreasing cell apoptosis (Figure 4G). Accordingly, the tumor suppressive role of PARK2 was further supported.

Overexpression of PARK2 Inhibits Tumor Growth in a Murine Subcutaneous Xenograft Model

A subcutaneous BALB/c nu/nu nude mouse xenograft model with H1299-PARK2 and H1299-NC cells was established by subcutaneous injection (n = 12) to explore the effect of PARK2 on tumor growth in vivo (Figure 5A). Tumor volumes and body weight of mice were measured every 3 days. After 4 weeks, the tumor growth was significantly delayed in the H1299-PARK2 group relative to the H1299-NC group, and the tumor volume and tumor weight of the two groups were 1531 ± 211.8 vs. 2665 ± 351.0 mm³ and 1.51 ± 0.23 vs. 2.41 ± 0.33 g (P < 0.05; Figure 5A). Higher expression of PARK2 in xenograft tumors of the H1299-PARK2 group than that of the H1299-NC group was confirmed by IHC and Western blot (Figures 5B,C). Consistently, fewer positive cells in PARK2 overexpression subcutaneous xenografts were detected by IHC Ki-67 assays (Figure 5D). Hematoxylin and eosin (H&E) staining confirmed the presence of more necrosis in the tumor nodules of the H1299-PARK2 xenograft than in the H1299-NC xenograft (Figure 5E). Figure 5F showed that the overexpression of PARK2 induced more cell apoptosis in the H1299-PARK2 group than that in the control group, as detected by TUNEL staining (P < 0.05).

PARK2 Attenuates the Occurrence of Metastasis in Mice

The stable transfection of H1299-PARK2 and H1299-NC cells were employed to construct a metastatic model through tail vein injection of nude mice (Figure 5G). After 6 weeks, no visible tumor nodules were observed in the H1299-PARK2 group. However, two mice in the H1299-NC group had visible tumor nodules on their lung surfaces (Figure 5G). Multiple metastases were also observed in subcutaneous tissue, muscles and sacrum (Figure 5G). Tumor sections were subjected to H&E staining (Figure 5H). In summary, the results strongly
suggested that PARK2 significantly inhibited tumor progression and metastasis in vivo.

**PARK2 Inhibits the EGFR/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway**

Western blot assay showed that EGFR was downregulated by the overexpression of PARK2 in H1299 and H460 cells (Figure 6A). Meanwhile, p-EGFR, p-AKT, and p-mTOR were clearly suppressed by PARK2 (Figure 6A). The effect of PARK2 under EGF stimulation (50 ng/mL EGF for 5 min) was investigated to confirm these results. Moreover, the overexpression of PARK2 significantly mitigated the EGF-induced protein expression of p-EGFR, p-AKT, and p-mTOR. Comparatively, knockdown of PARK2 elevated the levels of these phosphorylated proteins (Figure 6B). AKT and mTOR were unaltered following PARK2 overexpression or knockdown.
FIGURE 3 | Overexpression of PARK2 induces cell apoptosis and inhibits the migration and invasion of H1299 and H460 cells. (A) After annexin V-APC and 7-aminoactinomycin (7-AAD) double staining by flow cytometry analysis, cell apoptosis assay illuminated that Q2 showed the late apoptotic cells and Q3 showed the early apoptotic cells. (B) Cell apoptosis was confirmed by Hoechst 33342. (C) Upregulation of apoptosis-related proteins in PARK2 overexpression cells was verified by western blot assay. (D) Overexpression of PARK2 inhibited cell migration ability and cell invasive ability (magnification ×400). (E) In wound healing assay, the results confirmed that PARK2 decreased the migration ability of lung cancer cells. (F) PARK2 caused a decrease in cell migration and invasion and regulated the expression of key EMT proteins as verified by western blot assay *P < 0.05.
DISCUSSION

PARK2 alterations were originally recognized as a causal factor for Parkinson’s disease (9). The study subsequently showed that PARK2 was located in the common fragile site (CFS) region in FRA6E as a tumor suppressor. However, the CFS region frequently caused genomic instability by deletions and alterations, particularly in cancer cells (28). Previous studies reported that mutation or loss of PARK2 might be associated with tumorigenicity by regulating cell growth, cell cycle and mitochondrial biogenesis (29–31). Although several studies suggested that PARK2 is associated with lung cancer, the clear and comprehensive biological functions of PARK2 in NSCLC remain unclear (23, 32).

In this study, we observed that the expression of PARK2 was reduced in human NSCLC tissues compared with their adjacent non-neoplastic tissues by Western blot and IHC staining assays, which are consistent with study in colorectal cancer (33). PARK2 expression was associated with advanced TNM stage, lymph node metastasis and histological grade. Also, the expression of PARK2 between adenocarcinoma and squamous carcinoma have not statistically significant difference. Furthermore, PARK2 was aberrantly expressed in NSCLC cell lines. This study elucidated the biological functions and the underlying molecular mechanism of PARK2 in NSCLC in vitro and in vivo.

PARK2 was assumed to be involved in cell cycle progression (34). Gong et al. reported that PARK2 mediated the degradation of cyclin D1 by the proteasome, as the proteasome inhibitor MG132 could reverse it (29). Inactivation of PARK2 accounts for the abnormal accumulation of cyclin D and cyclin D–CDK4 complex, which eventually accelerates cell cycle progression (29). Cyclin D–CDK4 activity is restrained by P21 and P18, which are potent inhibitors of G1–S cell cycle transition (35). Moreover, CDK2 is the pivotal cell cycle regulator in the S phase and G2 phase (36). In the present study, PARK2 arrested a significant percentage of NSCLC cells at the G1 phase, upregulated the activation of P21 and P18, downregulated the activation of cyclin D1, cyclin D3, and CDK4 and reduced the Ki-67 index. Moreover, the decreased S phase cells were confirmed by the reduction in CDK2 expression. Meanwhile, overexpression of PARK2 significantly suppressed NSCLC cell proliferation and colony formation. These findings were consistent with the PARK2 knockdown results, which showed that PARK2 deficiency promoted cell proliferation and colony formation.
As we know, when apoptosis is inhibited and cell cycle progression is uncontrolled, malignant transformation of cells increases. Similarly, our study determined that PARK2 induced more apoptosis in NSCLC cells in vitro and increased expression of protein cytochrome c, caspase-3, caspase-8, and caspase-9 and cleaved PARP. Caspase-3 effectors were triggered by activated caspase-8 and caspase-9. Then, the proteolytic cleavage of PARP was further triggered during

FIGURE 5 | Subcutaneous xenografts and metastasis confirmed the suppressive effect of PARK2 on in vivo: (A) The image of tumor growth in nude mice subcutaneously injected with H1299-PARK2 and H1299-NC cells. Tumor volumes and weight were compared. (B–C) PARK2 protein levels in a murine subcutaneous xenograft model, as confirmed by IHC staining (left panels: magnification × 40, right panels: magnification × 400) and western blot assay. (D) As measured by IHC Ki-67, fewer proliferating cells were evaluated in PARK2-expressing subcutaneous xenografts (left panels: magnification × 40, right panels: magnification × 400). (E) More cell necrosis was confirmed by H&E staining of H1299-PARK2 tumor nodules in a subcutaneous xenograft model (left panels: magnification × 40, right panels: magnification × 400). (F) As detected by TUNEL staining, more apoptotic cells were evaluated in the H1299-PARK2 subcutaneous xenografts. (G) Multiple metastases in the muscles and sacrum were significantly detected in the H1299-NC group of metastatic models. (H) The lung transfer xenograft model was verified by H&E staining. *P < 0.05.
FIGURE 6 | PARK2 inhibits EGFR/AKT/mTOR signaling. (A) Western blot analysis showed that overexpression of PARK2 could suppress EGFR and other phosphorylated targets and mitigate EGF-stimulated conditions (50 ng/mL EGF for 5 min). (B) Conversely, knockdown of PARK2 promoted the pathway. However, AKT and mTOR were not altered. (The proteins were run on different gels).

the apoptotic process (37–39). Moreover, the subcutaneous xenograft model illustrated that PARK2 highly attenuated tumorigenesis and development of NSCLC in nude mice. In addition, further pathological analysis showed that significantly more proliferative cells and less apoptotic cells were detected in the subcutaneous xenograft tumors of the negative control group. Consistent with previous findings (40), PARK2 suppressed NSCLC cell proliferation and induced apoptosis.

Next, we explored the mechanisms underlying PARK2-inhibited metastasis. The data showed that overexpression of PARK2 significantly suppressed migration and invasion of NSCLC cells in vitro and dramatically reduced metastatic nodules in vivo. EMT contributes pathologically to cancer progression by promoting mesenchymal adhesion. In particular, the downregulation of E-cadherin and the upregulation of N-cadherin altered cell adhesion and contributed to tumor metastasis (41–43). In the present study, we found that PARK2 reduced invasion by regulating several important members of the EMT, including upregulating E-cadherin and downregulating N-cadherin, vimentin, slug, and claudin-1.

The PI3K/AKT/mTOR signaling pathway plays a vital role in processes related to cell growth, proliferation, metabolism, migration, and survival. Abnormal activation of the pathway is linked to diseases and tumorigenesis (44–48). Lin et al. identified that EGFR and its downstream pathway were potently suppressed by ubiquitination of PARK2 in glioma. Therefore, dysfunction of PARK2 led to the deficiency of E3 ligase and upregulation of the EGFR/AKT pathway (49). Using a similar approach, Yeo et al. (50) determined that the overexpression of PARK2 downregulated AKT phosphorylation in U87 cells. A recent report showed that the depletion of PARK2 enhanced the activation of PI3K/AKT/mTOR and played an important role in maintaining the activation of PENT, which was a well-known tumor suppressor that inhibits the PI3K/AKT pathway (51). Consistent with previous findings, our study confirmed that PARK2 exerted a tumor suppressive effect by regulating the activation of EGFR in NSCLC and inhibiting p-EGFR, p-AKT, and p-mTOR. Thus, overexpression of PARK2 in NSCLC cells reduced the level of cyclin D1 and N-cadherin and enhanced expression of caspase-3 and E-cadherin. Ultimately, PARK2 regulated the expression of those critical proteins by altering the activity of EGFR, AKT, and mTOR. These findings elucidated the underlying mechanisms of the tumor suppressive property of PARK2 in NSCLC, which inhibited the EGFR/AKT/mTOR pathway to suppress growth, metastasis and promotes apoptosis of NSCLC cells. Moreover, these findings indicated that PARK2 acts as a tumor suppressor gene and negatively regulates tumorigenesis through multiple pathways.

CONCLUSION

In summary, we have identified that PARK2 acted as a tumor suppressor gene that negatively regulates tumorigenesis and progression in NSCLC. PARK2 exerts a tumor suppressive function in vitro and in vivo, including retarding growth, migration, invasion, and metastasis and promotes apoptosis of NSCLC cells through inhibition of the EGFR/AKT/mTOR pathway. These results improve our understanding of NSCLC progression and supports PARK2 as a novel biomarker for NSCLC.

DATA AVAILABILITY

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

This research was approved by the Ethics Committee of the second Affiliated Hospital, School of Medicine, Zhejiang
University, which is accredited by the National Council on Ethics in Human and Animal Research.

**AUTHOR CONTRIBUTIONS**

SZ and CP conceived the study and provided suggestions and supervision of the study. HD and ZL participated in experiments. TP and DL contributed to the tissue specimens. CZ contributed to data analysis. All authors corrected draft versions and approved the final version of the manuscript.

**REFERENCES**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. (2015) 65:87–108. doi: 10.3322/caac.21262
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. (2011) 61:69–90. doi: 10.3322/caac.20107
3. Chen W, Zheng R, Baade PD, Zeng S, Zeng H, Bray F, et al. Somatic mutation of PARK2 tumor suppressor gene in Human and Animal Research. *Cancer Res*. (2009) 69:2937–42. doi: 10.1158/0008-5472.CAN-08-2894
4. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. *Lancet*. (2016) 388:1012–24. doi: 10.1016/S0140-6736(16)31473-8
5. Miller KD, Siegel RL, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin*. (2016) 66:271–89. doi: 10.3322/caac.21349
6. Heuvers ME, Hegmans JP, Stricker BH, Aerts JG. Improving lung cancer survival; time to move on. *BMC Pulm Med*. (2012) 12:77. doi: 10.1186/1471-2466-12-77
7. Rossel R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. *Lancet*. (2013) 382:720–31. doi: 10.1016/S0140-6736(13)61715-8
8. Mohamad N, Jayalakshmi P, Rhodes A, Laim CK, Tan JL, Yousouf S, et al. Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung. *Br J Biomed Sci*. (2017) 74:176–80. doi: 10.1080/09674845.2017.1331520
9. Kimura Y, Akimoto S, Nakamura M, Yamamura Y, Minoshima S, et al. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. *Nature*. (1998) 392:605–8. doi: 10.1038/33416
10. Shirahata H, Nakamura S, Kuroda M, Nakamura M, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet*. (2000) 23:302–5. doi: 10.1038/77060
11. Mitsui J, Takahashi Y, Goto J, Tomiyama H, Ishikawa S, Yoshino H, et al. Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cells. *Am J Hum Genet*. (2010) 87:75–89. doi: 10.1016/j.ajhg.2010.06.006
12. Shirahata H, Schlossmacher MG, Hattori N, Frosh MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson’s disease. *Science*. (2001) 293:263–9. doi: 10.1126/science.1060827
13. Trempe JF, Sauvé V, Grenier K, Serafi M, Tang MY, Ménade M, et al. Structure of the manuscript. *Mechanisms of genomic instabilities underlying two common fragile-site-associated loci*. *Proc Natl Acad Sci USA*. (2003) 100:5956–61. doi: 10.1073/pnas.0331261100
14. Xu L, Lin DC, Yin D, Koehler HP. An emerging role of PARK2 in cancer. *J Mol Med*. (2014) 92:31–42. doi: 10.1007/s00109-013-1107-0
15. Je EM, Yoo NI, Lee SH. Somatic mutation of PARK2 tumor suppressor gene is not common in common solid cancers. *Pathol Oncol Res*. (2013) 19:393–5. doi: 10.1007/s12253-012-9591-z

**FUNDING**

This work was funded by Zhejiang Provincial Natural Science Foundation of China (No. LQ17H160012), Key Laboratory of Cancer Prevention and Intervention of the China National Ministry of Education, Research Center for Air Pollution and Health, School of Medicine, Zhejiang University, the Nature Science Fund of China (No. 81602716), the Nature Science Fund of China (No. 81602516), and the Xinjiang Provincial Natural Science Foundation of China (No. 2015211C132).

This work was funded by the Ministry of Science and Technology of the People’s Republic of China (Nos. 2016YFA0301900 and 2017YFA0303800), the National Key R&D Program of China (Nos. 2016YFC0800403 and 2017YFC0910603), the Zhejiang Provincial Special Funding (No. 2017C01050), the National Natural Science Foundation of China (Nos. 81730063, 91748402, 81671039, and 81571164), and the Key Research and Development Program of Zhejiang Province (Nos. 2018C01109 and 2017C01050).
32. Lee S, She J, Deng B, Kim J, de Andrade M, Na J, et al. Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget. (2016) 7:44211–23. doi: 10.18632/oncotarget.9954

33. Bhat ZI, Kumar B, Bansal S, Naseem A, Tiwari RR, Wahabi K, et al. Association of PARK2 promoter polymorphisms and methylation with colorectal cancer in North Indian population. Gene. (2019) 682:25–32. doi: 10.1016/j.gene.2018.10.010

34. Teixeira LK, Reed SI. Ubiquitin ligases and cell cycle control. Annu Rev Biochem. (2013) 82:387–414. doi: 10.1146/annurev-biochem-060410-105307

35. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. (2000) 36:3–7. doi: 10.1016/S1368-8375(99)00049-4

36. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. (2015) 14:130–46. doi: 10.1038/nrd4504

37. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. (2013) 5:a008656. doi: 10.1101/cshperspect.a008656

38. Charan RA, Johnson BN, Zaganelli S, Nardozzi JD, LaVoie MJ. Inhibition of apoptotic Bax translocation to the mitochondria is a central function of parkin. Cell Death Dis. (2014) 5:e1313. doi: 10.1038/cddis.2014.278

39. Johnson BN, Berger AK, Cortese GP, Lavoie MJ. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Proc Natl Acad Sci USA. (2012) 109:6283–8. doi: 10.1073/pnas.1113248109

40. Fujiiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene. (2008) 27:6002–11. doi: 10.1038/onc.2008.199

41. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. (2014) 15:178–96. doi: 10.1038/nrm3758

42. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. (2009) 28:15–33. doi: 10.1007/s10555-008-9169-0

43. Theveneau E, Mayor R. Cadherins in collective cell migration of mesenchymal cells. Curr Opin Cell Biol. (2012) 24:677–84. doi: 10.1016/j.jcb.2012.08.002

44. Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. (2015) 141:671–89. doi: 10.1007/s00432-014-1803-3

45. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. (2007) 129:1261–74. doi: 10.1016/j.cell.2007.06.009

46. Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, et al. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway. Neuroendocrinology. (2012) 96:228–37. doi: 10.1159/000337257

47. Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, et al. Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. (2017) 23:4919–28. doi: 10.1158/1078-0432.CCR-16-2656

48. Yang H, Rudge DG, Koos JD, Vaidalingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. (2013) 497:217–23. doi: 10.1038/nature12122

49. Lin DC, Xu L, Chen Y, Yan H, Hazawa M, Doan N, et al. Genomic and functional analysis of the E3 ligase PARK2 in glioma. Cancer Res. (2015) 75:1815–27. doi: 10.1158/0008-5472.CAN-14-1433

50. Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK, et al. Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res. (2012) 72:2543–53. doi: 10.1158/0008-5472.CAN-11-3060

51. Gupta A, Anjomani-Virmouni S, Koundouro N, Dimitriadi M, Choo-Wing R, Valle A, et al. PARK2 depletion connects energy and oxidative stress to PI3K/Akt activation via PTEN S-nitrosylation. Mol Cell. (2017) 65:999–1013.e7. doi: 10.1016/j.molcel.2017.02.019

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Duan, Lei, Xu, Pan, Lu, Ding, Zhu, Pan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.